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The functional properties of the G protein-coupled
P2Y1 receptor were investigated in Xenopus oocytes. In-
cubation of oocytes expressing either the human or tur-
key P2Y1 receptor with adenine nucleotide agonists re-
sulted in an increase in Cl2 current and activation of a
novel cation current with an inwardly rectifying cur-
rent-voltage relationship. Activation of either the hu-
man P2Y2 (P2U-purinergic) or M1 muscarinic receptor
expressed in oocytes resulted in an increase in Cl2 cur-
rent similar to that observed in P2Y1 receptor-express-
ing oocytes but had no effect on cation current. P2 re-
ceptor agonists stimulated both the cation current and
Cl2 current in P2Y1 receptor-expressing oocytes with
EC50 values and an order of potency (2-methylthio-
adenosine diphosphate > 2-methylthioadenosine tri-
phosphate (2MeSATP) > ATP > UTP) that were similar
to those previously observed for activation of phospho-
lipase C in 1321N1 human astrocytoma cells stably ex-
pressing the human or turkey P2Y1 receptor. The P2Y
receptor antagonists suramin and pyridoxal phosphate
6-azophenyl-2*-4*-disulfonic acid both shifted to the
right the concentration-response relationship for 2Me-
SATP for stimulationof oocyte currents. Although injection
of oocytes with either GDPbS (guanyl-5*-yl thiophosphate)
or GTPgS (guanosine 5*-3-O-(thio)triphosphate) resulted in
loss of adenine nucleotide-promoted Cl2 channel activa-
tion, neither guanine nucleotide altered the 2MeSATP-
stimulated cation current. These data are consistent with
the view that activation of the novel cation current by the
P2Y1 receptor does not involve a G protein. Tail current
analysis of the novel P2Y1 receptor-associated cation con-
ductance revealed that the open channel current-voltage
relationship was outwardly rectifying with a reversal po-
tential of 238mV for the turkey P2Y1 receptor and 236mV
for the human P2Y1 receptor. Replacement of Na
1 with K1
ions in the bathing solution produced a shift in reversal
potential to near zero mV, but significant outward rectifi-
cation remained. The cation current was not permeable to
either Ca21 or Ba21 and exhibited steady-state inactivation
at holding potentials below 260 mV. These results indicate
that the P2Y1 receptor exhibits both metabotropic proper-
ties andanovelGprotein-independent ionotropic response
when expressed in Xenopus oocytes.
Extracellular adenine nucleotides regulate a variety of cel-
lular events through interaction with P2 receptors (1–4). This
receptor family was originally subclassified into the P2X and
P2Y receptor subtypes (5), and additional subtypes subse-
quently were proposed on the basis of differences in pharma-
cological and signaling properties (1, 2, 6).
P2X receptors possess ionotropic properties, promote con-
traction of a variety of smooth muscle preparations, and are
widely distributed in the central nervous system (1, 7–9). These
receptors function as non-selective cation channels and pro-
duce membrane depolarization upon activation by ATP. The
P2Y receptor was originally characterized as a receptor(s) that
mediated ATP-induced smooth muscle relaxation in rabbit por-
tal vein and guinea pig taenia coli. The P2Y receptor also was
found to be activated by 2MeSATP1 but not by P2X selective
agonists such as a,b-methylene ATP or b,g-methylene ATP (5).
Multiple P2Y receptors are now known to exist and most of
these couple to the Gq family of G proteins and promote inositol
lipid hydrolysis (2, 3, 10).
A phospholipase C-activating receptor (P2Y1 receptor) has
been cloned from chick (11), turkey (12), and several mamma-
lian species (13), including human (14). Stable expression of the
P2Y1 receptor in a null cell line confers pharmacological prop-
erties similar to those originally ascribed to P2Y receptors in
many tissues. The primary sequence of this receptor is typical
of members of the superfamily of G protein-coupled receptors
and predicts the presence of seven a-helical transmembrane
domains with an extracellular N terminus and an intracellular
C terminus. Three additional P2Y receptor family members
have been cloned. The P2Y2 receptor is analogous to the orig-
inally described P2U-purinergic receptor and is activated by
ATP and UTP (1, 15). The two most recently cloned members of
this family are selectively activated by uridine nucleotides
(16–19).
In a previous study, stable expression of the cloned turkey
(12) or human (14) P2Y1 receptors in 1321N1 human astrocy-
toma cells conferred an inositol lipid signaling response upon
addition of purinergic agonists. Here we describe the functional
properties of the turkey and human P2Y1 receptors expressed
in Xenopus oocytes. We report that incubation of P2Y1 receptor-
expressing oocytes with adenine nucleotides not only results in
activation of a Ca21-dependent Cl2 current as expected for a
phospholipase C-coupled receptor (20, 21), but also activates an
inwardly rectifying non-selective cation current that has not
been described previously. The novel P2Y receptor-associated
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current is not dependent on G protein activation and functional
characterization suggests that at least one member of the su-
perfamily of G protein-coupled receptors can produce ionotropic
responses that are dependent on receptor expression alone.
EXPERIMENTAL PROCEDURES
Materials—Xenopus laevis frogs were purchased from Xenopus I
(Ann Arbor, MI) and maintained in aquaria as suggested by the sup-
plier. Collagenase, penicillin, and gentamicin were obtained from Life
Technologies, Inc. 2MeSATP, 2-methylthioadenosine diphosphate
(2MeSADP), pyridoxal phosphate 6-azophenyl-29-49-disulfonic acid
(PPADS) and suramin were obtained from Research Biochemicals Inc.
(Natick, MA). Adenosine triphosphate (ATP) and uridine triphosphate
(UTP) were obtained from Sigma.
Oocyte Isolation and Injection—Ovarian lobes from adult Xenopus
frogs were removed from anesthetized animals under sterile conditions.
The tissue mass was dissociated with collagenase solution (in mM: 90
NaCl, 1 KCl, 0.82 MgSO4, 10 HEPES (pH 7.4), 250 units/ml collagen-
ase), and Stage V and VI oocytes were sorted, defolliculated, and main-
tained in standard amphibian Ringer solution (in mM: 90 NaCl, 1 KCl,
0.82 MgSO4, 0.74 CaCl2, 10 HEPES, pH 7.4, supplemented with 100
IU/ml penicillin and 50 mg/ml gentamicin) at 19–20 °C. After a 2–3-h
recovery period, the eggs were injected with cRNA transcripts (25–50
ng/oocyte). Injections were performed with a Drummond Nanoject oo-
cyte injection system, which electronically controls the volume (46 nl)
delivered into the oocyte. Control eggs were injected with 46 nl of sterile
water. Oocytes were stored for 2–7 days in amphibian Ringer solution
supplemented with 100 IU/ml penicillin and 50 mg/ml gentamicin at
19–20 °C.
Preparation of RNA for Injection—cRNA was synthesized from linear
cDNA encoding either the turkey P2Y1 (12), the human P2Y1 (14), the
human P2Y2 (22), or the human M1 muscarinic receptor (23) using
Ambion Megascript.
Electrophysiological Measurements—Electrophysiological measure-
ments were made using the two-electrode voltage clamp (Dagan TEV-
200) technique at 20 °C. Recordings were made in amphibian Ringer
solution containing (in mM) 90 NaCl, 1 KCl, 0.82 MgCl2, 0.74 CaCl2, 10
HEPES (pH 7.4) beginning 12–15 h after injection. Current- and volt-
age-measuring electrodes were pulled from borosilicate filament glass
to resistances between 0.5 and 2 megohms, when filled with 0.5 M KCl.
Data acquisition and analysis were performed with a Compaq 486
microcomputer using pCLAMP software (Axon Instruments).
Statistics—Data presented in the current-voltage relationships and
concentration-response relationships represent the mean 6 standard
error. Student’s t test for paired or unpaired means was used to deter-
mine statistical significance. A value of p , 0.05 was considered signif-
icant. Information regarding number of oocytes used for each experi-
ment is given in the figure legends.
RESULTS
Expression of P2Y1 and Other G Protein-coupled Receptors in
Xenopus Oocytes—Voltage clamp analyses were carried out
with oocytes expressing the human P2Y1 receptor (Fig. 1).
Oocytes were held at 220 mV in amphibian Ringer solution
and sequentially stepped through a series of voltages from
2140 to 1140 mV in 20-mV increments. No ATP- or 2MeSATP-
promoted inward currents were detected in water-injected con-
trol cells using this protocol (data not shown). Likewise, no
inward currents were detected in P2Y1 receptor-expressing
oocytes in the absence of 2MeSATP (Fig. 1). However, addition
of 500 nM 2MeSATP to P2Y1 receptor-expressing cells resulted
both in a slowly activating inward current in response to hy-
perpolarizing voltage steps and an increase in outward current
in response to depolarizing voltage steps. The current was
inwardly rectifying at negative voltages and outwardly rectify-
ing at voltages above 160 mV with a reversal potential near
240 mV.
To determine if the inward current was uniquely associated
with P2Y1 receptors, two additional Gq/phospholipase C-cou-
pled receptors were expressed in oocytes. P2Y2 (P2U) receptor-
expressing oocytes were held at either 220 or 280 mV in
amphibian Ringer solution (Fig. 2) and subjected to the same
voltage step protocol described in Fig. 1. Control currents ex-
hibited a near-linear current-voltage relationship with a rever-
sal potential of 240 mV. Addition of 100 mM UTP elicited an
outwardly rectifying whole cell current and shifted the reversal
potential to 212 mV. Current activation was not altered over a
range of holding potentials from 280 to 220 mV. The time
course and current-voltage relationship of the UTP-activated
current in these cells was nearly identical to the current re-
sponse elicited by 100 mM carbachol in M1 muscarinic receptor-
expressing oocytes under identical experimental conditions
(data not shown) and to the 2MeSATP-promoted outward cur-
rent described above (Fig. 1). These currents likely were due to
opening of a Ca21-activated Cl2 channel secondary to elevation
of intracellular Ca21. To test this hypothesis, Ca21 levels were
elevated independently of receptor activation by incubation of
water-injected oocytes with thapsigargin or the calcium iono-
phore ionomycin. A Cl2 current was observed identical to that
occurring in response to agonists in P2Y1 receptor-, M1 recep-
tor-, and P2Y2 receptor-expressing oocytes (data not shown).
However, in contrast to the result with P2Y1 receptor-express-
ing oocytes, no inward cation current was detected in response
to elevation of intracellular Ca21 by thapsigargin or ionomycin.
Pharmacological Properties of the Expressed Human P2Y1
Receptor—Concentration-response relationships for agonist-
FIG. 1. Expression of human P2Y1 (hP2Y1) receptor cRNA in
Xenopus oocytes. Oocytes were held at 220 mV in amphibian Ringer
solution (in mM) 90 NaCl, 1 KCl, 0.82 MgCl2, 0.74 CaCl2, 10 HEPES (pH
7.4) and stepped through a series of voltages from 2140 to 1140 mV in
20-mV increments. A, representative tracing showing the effects of 0.5
mM 2MeSATP on the whole cell current. B, current-voltage relationship
showing that both inwardly and outwardly rectifying currents are as-
sociated with 2MeSATP stimulation (n 5 7). Data for cells incubated
with vehicle (open circles) or 0.5 mM 2MeSATP (filled circles) human
P2Y receptor are presented.
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promoted currents in P2Y1 receptor-expressing oocytes are pre-
sented in Fig. 3. The EC50 values for 2MeSADP, 2MeSATP,
ATP, and UTP were 0.008, 0.07, 3, and .70 mM, respectively,
for stimulation of the non-selective cation current (Fig. 4A),
and were 0.009, 0.08, 3, and .100 mM, respectively, for stimu-
lation of the outward Cl2 current (Fig. 3B). Therefore, the
potencies of P2Y agonists for stimulation of the two currents
were essentially identical and were very similar to those deter-
mined for stimulation of inositol phosphate accumulation in
cells lines expressing recombinant P2Y1 receptors (12, 14). The
effects of two compounds previously shown to competitively
antagonize P2Y1 receptors also were examined (Fig. 4). Co-
addition of 70 mM PPADS with various concentrations of
2MeSATP resulted in a 7.1-fold shift (from 0.07 to 0.5 mM) in
the EC50 for 2MeSATP. Co-addition of suramin (10 mM) pro-
duced a 4.3-fold shift (from 0.07 to 0.3 mM) in the EC50 for
2MeSATP. The concentrations of PPADS and suramin used in
these experiments did not significantly alter the maximum
current response to 2MeSATP (data not shown).
Effect of Guanine Nucleotides on P2Y1 Receptor-promoted
Responses—The deduced amino acid sequence of the P2Y1 re-
ceptor predicts a seven-transmembrane spanning protein typ-
ical of that of members of the superfamily of G protein-coupled
receptors. The signaling responses previously associated with
the P2Y1 receptor apparently occur secondarily to activation of
members of the Gq family of G proteins. Therefore, the poten-
tial role of G proteins in the 2MeSATP-promoted currents of
P2Y1 receptor-expressing oocytes was examined (Fig. 5). Oo-
cytes expressing the human P2Y1 receptor were injected with
0.2 nmol (estimated intra-oocyte concentration 5 400 mM) of
either GDPbS or GTPgS. Voltage was held at 220 mV and
stepped to either 2140 mV or 1120 mV to determine the effects
of G protein modulators on 2MeSATP (20 mM)-evoked inward
cation and outward Cl2 currents. Treatment with GDPbS in-
hibited the 2MeSATP-promoted Cl2 current but had no effect
on agonist-stimulated inward cation current. GDPbS also had
no effect on the action of thapsigargin (0.1 mM), indicating that
GDPbS did not block the calcium-activated Cl2 current at a
level distal to G protein activation. Injection of oocytes with
GTPgS promoted an outward Cl2 current in the absence of
2MeSATP and ablated any further effect of 2MeSATP on the
Cl2 current. In contrast, GTPgS alone did not induce the
inward cation current in the absence of 2MeSATP and also
had no effect on activation of the inward cation current by
2MeSATP. These results suggest that the P2Y1 receptor-pro-
moted inward cation current does not involve G protein
activation.
FIG. 2. Expression of P2Y2 receptor cRNA in Xenopus oocytes.
Oocytes were held at either 220 or 280 mV in amphibian Ringer
solution and subjected to the same voltage step protocol described in
Fig. 1. A, representative tracing showing the effects of 100 mM UTP on
the whole cell current. B, current-voltage relationship showing that an
outwardly rectifying current is associated with UTP stimulation. Con-
trol currents (open circles) exhibited a near-linear current-voltage rela-
tionship with a reversal potential of 240 mV. Addition of 100 mM UTP
(filled circles) shifted the reversal potential to 212 mV (n 5 5). Chang-
ing the holding potential from 280 to 220 mV (inverted triangles) did
not significantly affect current activation.
FIG. 3. Pharmacological selectivity of adenine nucleotide-
stimulated currents. A, concentration-response relationship for the
hP2Y1-promoted current showing the effects of 2-MeSADP (open cir-
cles, n 5 6), 2MeSATP (filled circles, n 5 6), ATP (inverted triangles, n 5
6) and UTP (squares, n 5 5) on inward current elicited by step hyper-
polarization to 2140 mV (holding potential (hp) 5 220 mV). The EC50
values for each agonist were 0.008, 0.07, 3, and .70 mM, respectively. B,
Concentration-response relationship for the hP2Y1 current showing the
effects of 2MeSADP (open circles, n 5 6), 2MeSATP (filled circles, n 5
6), ATP (inverted triangles, n 5 6), and UTP (squares, n 5 5) on outward
current produced by step depolarization to 1120 mV (hp 5 220 mV).
The EC50 values for each agonist were 0.009, 0.08, 3, and .100 mM,
respectively.
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Holding Potential Sensitivity of the P2Y Current—The ade-
nine nucleotide-promoted current in human P2Y1 receptor-
expressing oocytes exhibited holding potential sensitivity with
respect to inward currents evoked by hyperpolarizing voltage
steps (Fig. 6). Oocytes were voltage-clamped for 5 min at each
of several holding potentials from 280 to 0 mV. The cells were
stepped to 2140 mV to activate the current, and peak inward
current in responses to 0.5 mM 2MeSATP were plotted as a
function of holding potential. Steady-state inactivation was
observed at voltages below 260 mV. The increase in outward
Cl2 current was not affected by holding potential. Analysis of
the difference current derived from subtraction of whole cell
currents obtained at holding voltages of 280 mV and 220 mV
indicated that the agonist-stimulated cation current in P2Y1
receptor-expressing oocytes is inwardly rectifying with a rever-
sal potential of 240 mV (Fig. 7). Essentially identical results
were obtained irrespective of whether the human or turkey
homologues of the P2Y1 receptor were studied (Fig. 6).
Analysis of Tail Currents and the Near-instantaneous Cur-
rent-Voltage Relationship—Tail current analysis was carried
out for both the human and turkey P2Y1 receptor currents
following activation with 100 mM ATP (Fig. 8). Oocytes were
held at 220 mV in standard amphibian Ringer solution and
stepped to 2140 mV to activate the current. At the peak of
activation the oocyte was stepped through a series of depolar-
izing voltages from 160 to 280 mV to determine the near-
instantaneous (50 ms following the voltage step) current-volt-
age relationship and the deactivation time course. To control
for differences in the degree of P2Y receptor expression be-
tween oocytes, the magnitude of the evoked current was refer-
FIG. 4. Effects of P2Y receptor antagonists on the 2MeSATP-
stimulated inward current elicited by step hyperpolarization to
2140 mV (hp 5 220 mV). A, effects of 70 mM PPADS (n 5 6). PPADS
produced a shift in the EC50 from 0.07 to 0.5 mM. Control, open circles;
PPADS, filled circles B, effects of 10 mM suramin (n 5 7). Suramin
produced a shift in the EC50 from 0.07 to 0.3 mM. Control, open circles;
suramin, filled circles.
FIG. 5. Effects of GDPbS and GTPgS on 2MeSATP-promoted
currents in hP2Y receptor expressing Xenopus oocytes. Oocytes
expressing the hP2Y1 receptor were injected with 0.2 nmol (estimated
intra-oocyte concentration 5 400 mM) of either GDPbS (n 5 12) or
GTPgS (n 5 7). Oocytes were held at 220 mV and stepped to either
2140 mV or 1120 mV to determine the effects of G protein modulators
on 2MeSATP (20 mM) evoked inward and outward currents. Thapsigar-
gin (0.1 mM) was used as a positive control in the GDPbS experiments to
prove that GDPbS did not block the calcium-activated outward Cl2
current.
FIG. 6. Holding potential sensitivity of the tP2Y1 and hP2Y1
currents. Oocytes were voltage-clamped for 5 min at each of several
holding potentials from 280 to 0 mV. The cells were then stepped to
2140 mV to activate the current. A, representative tracing showing the
effects of holding potential on the whole cell current. B, peak inward
current responses were plotted as a function of holding potential
(tP2Y1, open circle, (n 5 12); hP2Y1, filled circle (n 5 5)).
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enced to the initial maximally activated current at 2140 mV.
The I-V relationships for the human and turkey P2Y1 receptors
were not significantly different from each other. Both were
outwardly rectifying with reversal potentials of 238 and 236
mV, respectively. Replacement of sodium with potassium in the
bathing solution produced a shift in the reversal potential to
near zero mV, indicating a greater selectivity for potassium
than sodium.
To determine whether the channel was permeable to diva-
lent cations, Na1 was replaced with barium in the bathing
solution of oocytes expressing the human P2Y1 receptor (Fig.
9). Incubation with 2MeSATP resulted in an increase in inward
current when sodium was present in the bathing solution.
However, when sodium was replaced with barium, no 2Me-
SATP-promoted increase in inward current was detected. A
decrease in basal inward current also was observed in each
case. Similar results were obtained in experiments in which
sodium was replaced with Ca21 in the bathing solution (data
not shown). Oocytes bathed in BaCl2-containing or CaCl2-con-
taining Ringer solution exhibited a significantly greater out-
ward current compared to oocytes in standard amphibian
Ringer solution. This difference was presumably due to the
higher Cl2 concentration in the BaCl2/CaCl2 Ringer solutions,
which results in an increased driving force for Cl2 entry into
the cell. Additional activation of the Ca21-activated Cl2 chan-
nel also may have resulted from Ca21 or Ba21 entry into the
cell.
Analysis of the Activation, Inactivation, and Deactivation
Gating Events—The voltage dependence of activation, inacti-
vation, and deactivation was examined by measuring the time
constants for these gating events obtained from the experi-
ments described in Figs. 1, 7, and 8. Time constants for acti-
vation and inactivation were obtained by fitting the currents
produced by the activation protocol from Fig. 1 with the sum of




(2t/t3)). Two exponentials were
required to fit the activation process, and a single exponential
was sufficient to fit the process of inactivation (activation at
2140 mV: t1 5 0.07 6 0.006 s, t2 5 0.14 6 0.015 s; inactivation
at 2140 mV: t3 5 0.67 6 0.1 s). There was little voltage
dependence associated with activation or inactivation. Deacti-
vation time constants were obtained by fitting the current
traces from tail current experiments described in Fig. 8. Deac-
tivation was well described by a single exponential function
from the current peak to the end of the voltage step and
FIG. 7. Difference current analysis of the hP2Y1 current. A,
representative tracings showing the effects of holding potential on the
whole cell current in the presence of 0.5 mM 2MeSATP. B, current-
voltage relationship of the difference current between 220 and 280 mV
holding potentials (n 5 6).
FIG. 8. Tail current analysis of tP2Y1 and hP2Y1 currents fol-
lowing activation with ATP. A, representative tracing showing tail
currents from oocytes expressing the tP2Y receptor. Cells in the pres-
ence of 100 mM ATP were held at 220 mV and stepped to 2140 mV to
activate the current. At the peak of activation, the cell was stepped
through a series of depolarizing voltages from 160 to 280 mV to
determine the near-instantaneous (50 ms following the voltage step)
current-voltage relationship and the deactivation time course. B, near-
instantaneous current-voltage relationship for the tP2Y1 and hP2Y1
currents in amphibian Ringer solution and in high potassium Ringer
solution (in amphibian Ringer: tP2Y, open circle (n 5 10) and hP2Y1,
inverted triangle (n 5 8); high potassium Ringer: tP2Y1, filled circle
(n 5 6)). To control for differences in the degree of P2Y1 receptor
expression, the magnitude of the evoked current was referenced to the
initial maximum activated current at 2140 mV. The tP2Y1 and hP2Y1
I-V relationships were not significantly different from each other; both
were outwardly rectifying with reversal potentials of 238 and 236 mV,
respectively. Replacement of sodium in the bathing solution with po-
tassium (high potassium conditions) produced a shift in the reversal
potential to zero mV.
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exhibited voltage dependence over the range of 240 to 160 mV
(td at 160 mV 5 0.48 6 0.09 s; td at 280 mV 5 0.2 6 0.02 s).
Recovery from Inactivation—Recovery from inactivation was
studied in human P2Y1 receptor-expressing cells held at either
240 mV, 220 mV, or 0 mV in the continuous presence of
agonist (Fig. 10). Oocytes were subjected to a hyperpolarizing
voltage pulse to 2140 mV until complete inactivation was
observed. The voltage was then stepped back to the initial
holding potential for varying lengths of time, and reactivation
was promoted by hyperpolarization to 2140 mV. Peak inward
currents were plotted as a function of time and fit with a single
exponential function to determine the time constants for recov-
ery from inactivation at each holding potential (estimated t 5
6 s). No significant effect of holding potential on recovery from
inactivation was detected.
DISCUSSION
Expression of the P2Y1 receptor in Xenopus oocytes confers
an adenine nucleotide-activated cation current that has not
been recognized previously. Although P2Y1 receptor activation
also resulted in an increase in Cl2 permeability that occurs
with other Gq/phospholipase C-linked receptors (20, 21), hold-
ing potential sensitivity differentiated the effects of P2Y recep-
tor agonists on cation and Cl2 permeabilities through an anal-
ysis of the difference currents at 280 and 220 mV. Oocyte
expression of M1 muscarinic or P2Y2 receptors under the same
conditions conferred only the predicted Cl2 permeability in
response to agonists. Therefore, the novel cation permeability
associated with activation of the P2Y1 receptor is neither a
general property of Gq/phospholipase C-linked receptors nor of
the P2 receptor subclass of the G protein-coupled receptor
superfamily.
The unique adenine nucleotide-promoted cation current was
inwardly rectifying and had very little open probability at
holding voltages more negative than 240 mV. The open chan-
nel current-voltage responses associated with activation of both
the human and turkey P2Y receptors were outwardly rectifying
and reversed at voltages between 235 and 240 mV, suggesting
a greater selectivity for potassium than sodium. Replacement
of sodium with potassium in the bathing solution also resulted
in a shift in reversal potential to near zero mV, which indicates
that the cation channel was permeable to potassium. However,
a permeability ratio could not be accurately determined from
the tail current experiments since intracellular sodium and
potassium activities were unknown. Rectification cannot be
completely explained by the increased driving force for potas-
sium efflux at voltages above 0 mV, since significant outward
rectification was still apparent in high potassium Ringer solu-
tion. Thus, we suggest that outward rectification is an inherent
property of the pore. The P2Y1 receptor-associated cation cur-
rent does not involve passage of divalent cations, and the
inward current at voltages below 240 mV is carried by sodium
ions.
A minimum state gating model for adenine nucleotide-pro-
moted activation of a novel cation current is proposed (Gating
FIG. 9. Effects of sodium replacement with barium in the bath-
ing solution of oocytes expressing the hP2Y1 receptor. A, repre-
sentative tracing showing the effects of replacing extracellular sodium
with barium. B, current-voltage relationship showing that barium
replacement blocks inward current activation elicited by 0.5 mM
2MeSATP (n 5 6; open circle, control conditions; filled circle, stimula-
tion with 2MeSATP; inverted triangle, replacement with barium in the
presence of 2MeSATP). FIG. 10. Voltage dependence of recovery from inactivation. A,
representative tracing showing a recovery from inactivation record
obtained from a protocol where cells were held at either 240 mV, 220
mV, or 0 mV (hp 5 220 mV) in the continuous presence of agonist. B,
peak inward currents plotted as a function of time and fit with a single
exponential function to determine the time constants for recovery from
inactivation at each holding potential (hp 5 zero mV, inverted triangles
(n 5 5); hp 5 220 mV, open circles (n 5 5); hp 5 240 mV, filled circles
(n 5 5)).
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model). The time course of cation channel activation was slow,
requiring nearly 500 ms to achieve a maximal inward current.
Activation was well described by the sum of two exponentials,
suggesting that the channel may transit through at least two
closed states (C1 and C2) before it completely opens (O). Pro-
longed hyperpolarization in the continuous presence of agonist
resulted in a decrease in inward current and indicates the
existence of an inactivated state (I). Complete recovery follow-
ing inactivation required approximately 20 s at holding poten-
tials above 240 mV (I 3 C1) and exhibited no significant
voltage dependence. Finally, the deactivation process (O3 C1)
as revealed in tail current experiments was well described by a
single exponential function from the peak current to the end of
the voltage step and appeared to be the only gating process to
exhibit significant voltage dependence. The basis of the initial
time-dependent increase in outward current following steps to
positive voltages is not known. However, a similar phenomenon
was observed in tail current studies with a cardiac delayed-
rectifier potassium channel, where a time-dependent increase
in inward current was observed following hyperpolarization
from an initial depolarization step used for channel activation
(24). The unique gating properties of the P2Y1 receptor-acti-
vated cation current clearly distinguish it from previously char-
acterized ion channels in the Xenopus oocyte.
The pharmacological selectivities of adenine nucleotide ana-
logues for Cl2 and cation channel activation were similar to
those we previously observed for activation of phospholipase C
in 1321N1 cells expressing the human or turkey P2Y1 recep-
tors. In addition, 2MeSATP-promoted activation of the cation
current was blocked by both suramin or PPADS, which previ-
ously were shown to be competitive antagonists at the P2Y1
receptor. As predicted from previous studies of G protein-cou-
pled receptors expressed in Xenopus oocytes, injection of gua-
nine nucleotide analogs blocked the effects of P2Y1 receptor
activation on the Ca21-dependent Cl2 current. In contrast, no
effect of guanine nucleotides on P2Y1 receptor-promoted acti-
vation of the cation current was observed, which strongly sug-
gests that P2Y1 receptor-promoted increases in cation current
are not dependent on receptor coupling to endogenous G
proteins.
One interpretation of the results is that the expressed P2Y1
receptor possesses both metabotropic and ionotropic properties.
Since we are unaware of ion channel activity associated with
other G protein coupled receptors, the P2Y1 receptor may be a
member of a novel subset of the superfamily of G protein-
coupled receptors that exhibit ionotropic properties similar to
those of P2X receptors. These similarities would include in-
wardly rectifying current-voltage relationships and corre-
sponding selectivities for sodium and potassium. However, un-
like P2X receptors, the P2Y1 receptor exhibits voltage-
dependent inactivation and is not permeable to calcium (9).
Such discrepancies in functional properties may result from the
significant structural differences that exist between these two
purinergic receptor subtypes.
An alternative interpretation of the data in this study could
be that P2Y1 receptors possess a unique, G protein-independ-
ent mechanism for coupling to a previously uncharacterized
cation channel in Xenopus oocytes. This interpretation would
require that this cation channel not be activated by changes in
membrane potential or by activation of the inositol lipid sig-
naling cascade by M1 muscarinic or P2U receptors. In broad
ranging studies with the natively expressed or cloned P2Y1
receptors, we have seen no evidence for biochemical responses
to purinergic agonists other than those associated with activa-
tion of phospholipase C (12, 14, 25–27). A less likely possibility
is that expression of the P2Y1 receptor in Xenopus oocytes also
could promote transcription and subsequent expression of a
novel cation channel, which then was activated in an agonist-
dependent manner by a mechanism that does not require cou-
pling to endogenous G proteins.
Parker and Scarpa (28) recently described a slowly activat-
ing current in guinea pig ventricular myocytes that was stim-
ulated by ATP and 2MeSATP but not by a,b-methylene ATP or
UTP. This current was inwardly rectifying with a reversal
potential near zero mV. 2MeSATP-stimulated activation of this
non-selective cation current apparently was not G protein-de-
pendent, since internal perfusion would have significantly di-
luted any soluble constituents within the cell. A similar in-
wardly rectifying non-selective cation current also was
identified in dissociated neurons from the tuberomammillary
nucleus of the rat brain. 2MeSATP was found to be more potent
than a,b-methylene in producing activation of the channel, and
no effect of adenosine was observed (29). These results suggest
that a P2Y receptor was responsible for channel activation.
Thus, P2Y receptors that are natively expressed in at least one
population of CNS neurons and in guinea pig cardiac myocytes
activate a cation current that is similar to that observed in
oocytes expressing the cloned human or turkey P2Y1 receptor.
In summary, activation of a novel cation channel has been
shown to be associated with activation of the P2Y1 receptor
expressed in Xenopus oocytes. The results suggest dual func-
tionality of this G protein-coupled receptor. The functional and
structural bases of the apparently G protein-independent iono-
tropic properties of the P2Y1 receptor will need to be reconciled
with those of classically defined ionotropic receptors of much
different structure.
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